The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...
Nasdaq: Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in Adults First Novel Mechanism Therapy to Treat IBS-C in a Decade Product Now Available The approval ...
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
AOL: This Unexpected Type Of Treatment May Be A Surefire Way To Improve Your IBS Symptoms
This Unexpected Type Of Treatment May Be A Surefire Way To Improve Your IBS Symptoms
NEW IBS research highlights persistent pain treatment gaps and points to peripheral nerve targets for future, safer therapies. IBS Pain Remains a Major Clinical Gap. Pain remains ...
Seeking Alpha: Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
Jeffrey Lackner, PsyD, a pioneer in research on CBT for IBS, discusses barriers in access to treatment and the need for increased awareness. Irritable bowel syndrome (IBS) is characterized by ...
Medical Xpress: IBS treatment response predicted by gut microbiome in new study
Irritable bowel syndrome (IBS) is a common condition that affects the stomach and intestines, also called the gastrointestinal tract. Symptoms include cramping, belly pain, bloating, gas, and diarrhea or constipation, or both.